Biomodulina t + va-mengoc-bc
Biomodulina t + va-mengoc-bc has been studied in 1 paper since 2021: 1 trial in people. The newest paper, Jul 26, 2021: “Effect of Biomodulina-T® and VA-MENGOC-BC® on lymphocyte subpopulations in older adults”.
1 paper studies it1 findingUpdated
“combination treatments and V-BC did not generate statistically significant immunomodulatory changes in any of the studied lymphocyte subpopulations.”
- 1 lab in 1 country
- 1 of 1 finding with company ties
- Human trial1
Studies in people
1 study gave biomodulina t + va-mengoc-bc to people and measured what changed.
no change: Has no effect on lymphocyte subpopulations
Trial30 peopleover 65 years of age
Older adults
Experimental gerontology, Jul 26, 2021
What did studies of Biomodulina t + va-mengoc-bc find?
1Studies of Biomodulina t + va-mengoc-bc measured 1 outcome; the most studied are lymphocyte subpopulations (1 study).
Lymphocyte subpopulations
no changein humans1
1 study
Lymphocyte subpopulations
no changein humans1
Biomodulina t + va-mengoc-bc showed no clear effect on lymphocyte subpopulations in humans.
“combination treatments and V-BC did not generate statistically significant immunomodulatory changes in any of the studied lymphocyte subpopulations.”
Human trialn = 30
Effect of Biomodulina-T® and VA-MENGOC-BC® on lymphocyte subpopulations in older adults
Experimental gerontology